This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher (TMO) New Facility to Advance Lab Products Supply
by Zacks Equity Research
Thermo Fisher's (TMO) new manufacturing facility will help the United States meet demand surges for vital laboratory products.
Bruker (BRKR) Advances in Proteomics Workflow With New Pacts
by Zacks Equity Research
Talking about these three developments, Bruker (BRKR) notes that because of complex sample preparation protocols, the widespread adoption of proteomics has been limited.
Illumina (ILMN) iHope Genetic Health Program Expands WGS Access
by Zacks Equity Research
Illumina's (ILMN) launch of iHope Genetic Health program will expand access to WGS to low- and middle-income communities worldwide.
NuVasive (NUVA) Up on Rumors of Takeover by Globus Medical
by Zacks Equity Research
NuVasive's (NUVA) declining spine implant business might get a boost if its consolidation with Globus Medical takes place.
Here's Why You Should Retain STERIS (STE) Stock For Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to its strong fiscal second-quarter results and bullish 2022 outlook.
Medtronic's (MDT) PillCam SB3 System Gets 510 (k) Clearance
by Zacks Equity Research
Medtronic's (MDT) PillCam SB3 System provides a convenient option for a contactless procedure and helps ensure that patients can access care promptly.
Abbott (ABT) Aveir System Meets Primary Pivotal Trial Endpoints
by Zacks Equity Research
Abbott's (ABT) Aveir pacing system has the potential to advance treatment for patients who need a pacemaker but where physicians are concerned about more invasive surgery.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by consistent recovery across its businesses and raised 2021 guidance.
Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves
by Zacks Equity Research
Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.
Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat
by Zacks Equity Research
Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong third-quarter results and bullish 2021 guidance.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) revenues in the third quarter of 2021.
Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows
by Zacks Equity Research
Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.
Cardiovascular Systems (CSII) Q1 Loss Wider Than Expected
by Zacks Equity Research
Cardiovascular Systems' (CSII) coronary franchise registers strong performance globally on continued strength in Japan and Europe.
SmileDirectClub (SDC) Q3 Earnings Lag Estimates, Margin Grows
by Zacks Equity Research
SmileDirectClub (SDC) registered a year-over-year decline in revenues in the third quarter due to lower unique aligner shipment.
Hill-Rom (HRC) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Strong underlying performance and continued recovery across all three business segments drove Hill-Rom's (HRC) fourth-quarter fiscal 2021 revenues.
Insulet (PODD) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
STERIS (STE) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Solid growth across all three reporting segments drove STERIS' (STE) second-quarter fiscal 2022 revenues.
Tandem Diabetes (TNDM) Q3 Earnings Top Estimates, Sales View Up
by Zacks Equity Research
Tandem Diabetes (TNDM) reports better-than-expected revenues for third-quarter 2021 as strong domestic and international pump shipments drive the top line.
Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.
CVS Health (CVS) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strength in all three operating segments drove CVS Health's (CVS) revenues in the third quarter of 2021.
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business registered an improvement in revenues during the third quarter on strong contributions from Cologuard volume growth.
Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.
Henry Schein (HSIC) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the third quarter.
Hologic (HOLX) Q4 Earnings Surpass Estimates, 2022 View Dull
by Zacks Equity Research
Impressive performance by the Breast Health and GYN Surgical segments drives Hologic's (HOLX) fiscal fourth-quarter revenues.